AbbVie vs Sanofi

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival...

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

JUVMO™ is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson's disease. Taken once daily with or without levodopa therapy, JUVMO offers patients a...

AbbVie Participates in USTR’s Section 301 Investigation into Germany to Address Global Imbalances in How Transformative Medicines are Valued

On behalf of AbbVie, Perry Siatis, Executive Vice President, General Counsel and Secretary, testified in front of the U.S. Trade Representative (USTR) on...

6-K Financial Filing Analysis for Sanofi (2026-10-30)

On October 30, 2026, Sanofi furnished a Form 6-K to the SEC incorporating a press release announcing its financial results for the third quarter ended September 30, 2026. The report highlighted double-digit growth in both net sales and business earnings per share (EPS). Driven by robust operational performance across key therapeutic areas, management upgraded its full-year 2026 financial guidance. The filing confirms continued commercial momentum and underscores positive operating leverage ahead of year-end reporting.

• Sanofi reported double-digit growth in both sales and business EPS for the third quarter of 2026.
• Management officially upgraded its full-year 2026 financial guidance as reflected in Exhibit 99.1.
• The Form 6-K was executed on October 30, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.

6-K Financial Filing Analysis for Sanofi (2026-10-26)

Sanofi filed a Form 6-K on October 26, 2026, incorporating a press release dated October 19, 2026, regarding the groundbreaking of a new state-of-the-art insulin manufacturing facility in Germany. The investment reinforces Sanofi's global production network and long-term manufacturing capacity for its diabetes care portfolio. This expansion aims to strengthen supply chain resilience, modernize biomanufacturing capabilities, and secure insulin supply across European and international markets.

• Sanofi initiated construction on a new state-of-the-art insulin manufacturing facility located in Germany.
• The underlying operational milestone was formally announced via an exhibit press release dated October 19, 2026.
• The Form 6-K report was executed and submitted to the SEC on October 26, 2026, by Alexandra Roger, Head of Legal Corporate & Finance.

6-K Financial Filing Analysis for Sanofi (2026-10-01)

On October 1, 2026, Sanofi filed a Form 6-K with the U.S. Securities and Exchange Commission announcing an expansion of its global alliance with Regeneron Pharmaceuticals. The collaboration will encompass multiple next-generation, long-acting immunology antibodies, building upon their established partnership responsible for blockbuster treatments such as Dupixent. This strategic move aligns with Sanofi's 'Play to Win' roadmap, reinforcing its specialty care pipeline and solidifying its leadership in large-market immunological therapies.

• Sanofi and Regeneron expanded their global alliance to develop and commercialize multiple next-generation, long-acting immunology antibodies as of October 1, 2026.
• The material agreement was formally reported to the SEC via Form 6-K under Exhibit 99.1.